Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
Table 3
Incidence of adverse events related to VTD regimen in each group.
Events (, %)
VTD group ()
Improved VTD group ()
P*
All grades
Grade ≥ 3
All grades
Grade ≥ 3
Leukopenia
27 (90%)
18 (60%)
22 (73.3%)
9 (30%)
5.455
0.020
Neutropenia
25 (83.3%)
13 (43.3%)
22 (73.3%)
12 (40%)
0.069
0.793
Thrombocytopenia
27 (90%)
19 (63.3%)
24 (80%)
16 (53.3%)
0.617
0.432
Anemia
15 (50%)
5 (16.7%)
12 (40%)
5 (16.7%)
0.000
1.000
Peripheral sensory neuropathy
17 (56.7%)
6 (20%)
10 (33.3%)
3 (10%)
1.176
0.278
Diarrhoea
11 (36.7%)
3 (10%)
10 (33.3%)
1 (3.3%)
1.071
0.301
Neuralgia
3 (10%)
1 (3.3%)
2 (6.7%)
0
1.107
0.313
Pyrexia
2 (6.7%)
0
1 (3.3%)
0
0.000
1.000
Nausea
18 (60%)
5 (16.7%)
10 (33.3%)
3 (10%)
0.577
0.448
Vomiting
14 (%)
4 (13.3%)
10 (33.3%)
3 (10%)
0.162
0.688
Asthenia
24 (80%)
5 (16.7%)
17 (56.7%)
3 (10%)
0.577
0.448
Constipation
12 (40%)
2 (6.7%)
9 (30%)
0
2.069
0.150
Fatigue
26 (86.7%)
11 (36.7%)
21 (70%)
4 (13.3%)
4.356
0.037
Weight decreased
3 (10%)
0
1 (3.3%)
0
0.000
1.000
Pneumonia
4 (13.3%)
0
2 (6.7%)
0
0.000
1.000
Eye disorders
2 (6.7%)
0
0
0
0.000
1.000
Renal and urinary disorders
21 (70%)
4 (13.3%)
13 (13.3%)
1 (3.3%)
1.964
0.161
Skin and subcutaneous tissue disorders
4 (13.3%)
1 (3.3%)
2 (6.7%)
0
1.107
0.313
Hepatobiliary disorders
6 (20%)
3 (10%)
4 (13.3%)
2 (6.7%)
0.218
0.640
Psychiatric disorders
1 (3.3%)
0
0
0
0.000
1.000
* shows that grade 3 and higher adverse events were compared by chi square test. VTD: bortezomib and thalidomide plus dexamethasone; improved VTD: subQ bortezomib and thalidomide plus dexamethasone.
